Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ombitasvir
- Development stage
- Phase 4
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ombitasvir is a direct acting antiviral agent used in combination with other antiviral agents for the treatment of chronic hepatitis C virus (HCV) infection. It is an inhibitor of the HCV nonstructural protein 5A (NS5A), which is essential for viral replication and assembly. Ombitasvir does not act as monotherapy but is part of fixed-dose combinations, most notably with paritaprevir and ritonavir (Technivie) or with paritaprevir, ritonavir, and dasabuvir (Viekira Pak). These regimens are indicated primarily for HCV genotypes 1 and 4. Ombitasvir-based therapies have demonstrated high rates of sustained virologic response (SVR), minimal side effects compared to older interferon-based regimens, and significant long-term health benefits including reduced liver-related damage[1][5][6].
- Brand names
- Viekira PakTechnivieViekira XR
- Other names
- ombitasvir
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on ombitasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ombitasvir.